Tenjarla Srini 4

What Happened
Tenjarla Srini, SVP, CMC & Formulation at Serina Therapeutics, was granted 85,558 derivative shares (transaction code A — grant/award) on May 21, 2026. The reported acquisition price is $0.00, so no cash was paid by the insider at grant; the filing lists the award as a derivative security (e.g., stock options or RSUs), not a market purchase or sale.

Key Details

• Transaction date: 2026-05-21; Form 4 filed May 26, 2026 (reporting period 2026-05-21).
• Quantity and price: 85,558 derivative shares granted at $0.00 (total reported cash cost $0).
• Shares owned after transaction: not specified in this filing.
• Footnote (vesting): 12/48ths of the option shares vest 12 months after the Vesting Commencement Date (one-year cliff), then 1/48th vests monthly thereafter until fully vested.
• Filing timeliness: filing date is shown; the report does not indicate an explicit timeliness flag.

Context
This was a compensation grant (an equity award) rather than an open-market buy or sale. Derivative awards typically convert to economic ownership only as they vest (or are exercised), and they do not represent immediate cash proceeds or sales by the insider. Retail investors should view this as routine equity compensation intended to retain or incentivize management; it is informational rather than a direct bullish/bearish trade signal.